Logo Image
Opinion|Videos|October 7, 2024

ECOSPOR Trials and Data with Fecal Microbiota Spores, Live-BRPK Oral Capsules (VAS) for C. difficile Infections

Paul Feuerstadt, MD, FACG, AGAF, discusses the key findings from the phase 3 ECOSPOR clinical trial for fecal microbiota spores, live-brpk oral capsules (VAS).

Episodes in this series

Video content above is prompted by the following:

  • Discussion of key findings from the phase 3 clinical trial for fecal microbiota spores, live-brpk oral capsules (VAS).
  • Comparing the two clinical trials, what were some significant differences between them?

Related to this article

View more
Asymptomatic C difficile Colonization in Infants Doesn’t Mean Benign
Asymptomatic C difficile Colonization in Infants Doesn’t Mean Benign
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.
Read more
Peggy Lillis Foundation Will Honor C diff Advocates at Annual Gala
Peggy Lillis Foundation Will Honor C diff Advocates at Annual Gala
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Read more